Last reviewed · How we verify

Cinnagen — Portfolio Competitive Intelligence Brief

Cinnagen pipeline: 0 marketed, 0 filed, 11 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 11 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Nephrovit Nephrovit phase 3 Nephrology
Pegylated interferon beta-1a Pegylated interferon beta-1a phase 3 Interferon IFNAR Immunology
Aflibercept (Regeneron, USA) Aflibercept (Regeneron, USA) phase 3 VEGF inhibitor (soluble decoy receptor) VEGF-A, VEGF-B, PlGF (Placental Growth Factor) Oncology, Ophthalmology
CinnaTropin® CinnaTropin® phase 3 Recombinant human growth hormone (somatropin) Growth hormone receptor (GHR) Endocrinology
Nordilet® Nordilet® phase 3 DPP-4 inhibitor DPP-4 Diabetes
Interferon Beta-1A Prefilled Syringe Interferon Beta-1A Prefilled Syringe phase 3 Interferon Type I interferon receptor (IFNAR) Immunology
CinnaPoietin® CinnaPoietin® phase 3 Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor (EPOR) Hematology/Oncology
Omalizumab (CinnaGen) Omalizumab (CinnaGen) phase 3 IgE monoclonal antibody Immunoglobulin E (IgE) Immunology / Allergy
Sulfonylurea/non-sulfonylurea insulin secretagogues Sulfonylurea/non-sulfonylurea insulin secretagogues phase 3 Insulin secretagogues SUR1 Diabetes
Cetuximab + FOLFIRI Cetuximab + FOLFIRI phase 3 Monoclonal antibody + chemotherapy combination EGFR (cetuximab component); Topoisomerase I (irinotecan component) Oncology
Ocrelizumab (CinnaGen, Iran) Ocrelizumab (CinnaGen, Iran) phase 3 CD20-targeting monoclonal antibody CD20 Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Hoffmann-La Roche · 3 shared drug classes
  2. Novartis · 2 shared drug classes
  3. Celltrion · 2 shared drug classes
  4. JW Pharmaceutical · 2 shared drug classes
  5. Amgen · 2 shared drug classes
  6. Ain Shams University · 2 shared drug classes
  7. Merck Sharp & Dohme LLC · 2 shared drug classes
  8. Sandoz · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Cinnagen:

Cite this brief

Drug Landscape (2026). Cinnagen — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cinnagen. Accessed 2026-05-16.

Related